Menin Inhibitors
Feb 06, 2026
Menin Inhibitors: A Revolutionary Treatment Paradigm for Acute Leukemia
Summary Menin inhibitors are an emerging class of targeted therapies that transform treatment for genetically defined acute leukemias, particularly KMT2A‑rearranged and NPM1‑mutated AML. REVUFORJ (revumenib, Syndax) is the first FDA‑approved selective menin inhibitor for relapsed/refractory acute leukemia wi...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
